Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS COMPASS Pathways	$3.26 -3.6%	$3.99	$2.25 ▼ $8.54	$305.01M	2.12	1.23 million shs	1.37 million shs
DVAX Dynavax Technologies	$10.28 +1.2%	$10.14	$9.22 ▼ $14.63	$1.23B	1.03	2.16 million shs	511,141 shs
KRON Kronos Bio	$0.88 +1.5%	$0.79	$0.65 ▼ $1.60	$53.72M	1.64	363,125 shs	54,089 shs
OCUL Ocular Therapeutix	$9.36 -1.1%	$8.19	$5.79 ▼ $11.78	$1.53B	1.43	1.41 million shs	1.16 million shs
RPTX Repare Therapeutics	$1.37 -4.9%	$1.39	$0.89 ▼ $4.29	$61.76M	0.84	247,615 shs	18,592 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS COMPASS Pathways	0.00%	+17.65%	-27.90%	+20.26%	-48.02%
DVAX Dynavax Technologies	0.00%	+3.73%	+3.94%	-18.74%	-6.72%
KRON Kronos Bio	0.00%	0.00%	+30.41%	+12.97%	-22.12%
OCUL Ocular Therapeutix	0.00%	+1.52%	+11.69%	+47.17%	+39.91%
RPTX Repare Therapeutics	0.00%	-1.44%	-5.52%	+37.01%	-56.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPS COMPASS Pathways	1.6502 of 5 stars	3.4	2.0	0.0	0.6	0.8	0.6
DVAX Dynavax Technologies	4.1987 of 5 stars	3.3	2.0	4.7	0.6	1.7	1.9
KRON Kronos Bio	3.4857 of 5 stars	3.2	3.0	0.0	0.0	4.2	1.3
OCUL Ocular Therapeutix	3.9429 of 5 stars	3.5	1.0	4.1	2.7	2.5	0.0
RPTX Repare Therapeutics	2.1258 of 5 stars	3.3	3.0	0.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	421.63% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	133.46% Upside
KRON Kronos Bio	2.33	Hold	$1.63	84.66% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.33	85.19% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	228.47% Upside

Current Analyst Ratings Breakdown

Latest CMPS, RPTX, DVAX, OCUL, and KRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/17/2025	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$12.00 ➝ $10.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
DVAX Dynavax Technologies	$277.25M	4.45	$0.16 per share	64.86	$4.54 per share	2.26
KRON Kronos Bio	$9.85M	5.45	N/A	N/A	$1.45 per share	0.61
OCUL Ocular Therapeutix	$63.72M	23.40	N/A	N/A	$2.01 per share	4.66
RPTX Repare Therapeutics	$53.48M	1.10	N/A	N/A	$3.56 per share	0.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	20.98	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
KRON Kronos Bio	-$86.08M	-$1.07	N/A	N/A	N/A	-701.53%	-64.22%	-47.17%	8/6/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$3.01	N/A	N/A	N/A	N/A	-78.12%	-67.11%	N/A

Latest CMPS, RPTX, DVAX, OCUL, and KRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS COMPASS Pathways	0.11	10.18	10.18
DVAX Dynavax Technologies	0.49	11.93	10.84
KRON Kronos Bio	N/A	12.93	12.93
OCUL Ocular Therapeutix	0.26	10.22	10.14
RPTX Repare Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS COMPASS Pathways	46.19%
DVAX Dynavax Technologies	96.96%
KRON Kronos Bio	64.09%
OCUL Ocular Therapeutix	59.21%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
CMPS COMPASS Pathways	3.93%
DVAX Dynavax Technologies	2.98%
KRON Kronos Bio	24.40%
OCUL Ocular Therapeutix	2.30%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
KRON Kronos Bio	100	61.05 million	46.16 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable
RPTX Repare Therapeutics	180	42.89 million	37.96 million	Optionable

CMPS, RPTX, DVAX, OCUL, and KRON Headlines

Recent News About These Companies

Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9% - Should You Sell?

July 4 at 2:21 AM | marketbeat.com

Repare Therapeutics Inc (RPTX) - Investing.com

July 3 at 5:41 PM | investing.com

Repare Therapeutics Inc (RPTX) Stock Forums - Investing.com

June 30, 2025 | investing.com

Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal

June 25, 2025 | insidermonkey.com

Repare Therapeutics Updates Severance Benefits for Executives

June 20, 2025 | tipranks.com

Repare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% - What's Next?

June 7, 2025 | marketbeat.com

Repare Therapeutics Strengthens Leadership with New Executive Appointment

June 2, 2025 | tipranks.com

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | financialpost.comF

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | financialpost.comF

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

Repare Therapeutics Inc. Common Shares (RPTX)

May 2, 2025 | nasdaq.com

Newly Launched DCx Biotherapeutics Inks Licensing Deal With Repare Therapeutics

May 1, 2025 | precisionmedicineonline.comP

Why Repare Therapeutics Inc.’s (RPTX) Stock Is Up 5.60%

April 29, 2025 | aaii.comA

Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics

April 15, 2025 | investing.com

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds

April 1, 2025 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)

April 1, 2025 | markets.businessinsider.com

Repare Therapeutics Names Forte as President, CEO

March 31, 2025 | marketwatch.com

Repare Therapeutics Announces Leadership Transitions

March 31, 2025 | businesswire.com

What Makes Repare Therapeutics (RPTX) a New Buy Stock

March 11, 2025 | zacks.com

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 7, 2025 | businesswire.com

Repare Therapeutics price target lowered to $5 from $10 at H.C. Wainwright

March 7, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, RPTX, DVAX, OCUL, and KRON Company Descriptions

COMPASS Pathways NASDAQ:CMPS

$3.26 -0.12 (-3.58%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$3.26 +0.00 (+0.03%)

As of 07/3/2025 04:59 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Dynavax Technologies NASDAQ:DVAX

$10.28 +0.12 (+1.18%)

Closing price 07/3/2025 03:20 PM Eastern

Extended Trading

$10.28 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Kronos Bio NASDAQ:KRON

$0.88 +0.01 (+1.49%)

As of 06/20/2025

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Ocular Therapeutix NASDAQ:OCUL

$9.36 -0.10 (-1.06%)

Closing price 07/3/2025 01:45 PM Eastern

Extended Trading

$9.62 +0.26 (+2.78%)

As of 07/3/2025 04:49 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Repare Therapeutics NASDAQ:RPTX

$1.37 -0.07 (-4.86%)

Closing price 07/3/2025 01:26 PM Eastern

Extended Trading

$1.38 +0.01 (+0.66%)

As of 07/3/2025 04:01 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time